BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:16 PM
 | 
Sep 09, 2008
 |  BC Extra  |  Company News

Pfizer withdraws dalbavancin applications

Pfizer (NYSE:PFE) withdrew an NDA in the U.S. and an MAA in Europe for dalbavancin to treat complicated skin and skin structure infections (cSSSIs). Dalbavancin received FDA approvable letters in 2005, 2006 and 2007....

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >